title: The limit for chronic myeloid leukemia relapse after allogeneic hematopoietic stem cell transplant moves ever forward: when can you safely talk about healing?
authors.forename: Anna Paola
authors.initials: AP
authors.lastname: Iori
authors.forename: Massimo
authors.initials: M
authors.lastname: Breccia
authors.forename: Corrado
authors.initials: C
authors.lastname: Girmenia
authors.forename: Salvatore
authors.initials: S
authors.lastname: Perrone
authors.forename: Veronica
authors.initials: V
authors.lastname: Valle
authors.forename: Fiammetta
authors.initials: F
authors.lastname: Natalino
authors.forename: Walter
authors.initials: W
authors.lastname: Barberi
authors.forename: Emilia
authors.initials: E
authors.lastname: Scalzulli
authors.forename: Giovanni Fernando
authors.initials: GF
authors.lastname: Torelli
authors.forename: Maria Cristina
authors.initials: MC
authors.lastname: Puzzolo
authors.forename: Robin
authors.initials: R
authors.lastname: Foà
mesh_terms: D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000235:genetics / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors; D014184:Transplantation, Homologous
chemical_list: D016044:Fusion Proteins, bcr-abl